Rivaroxaban (Xarelto) yl)ethane-1 2-diamine hydrochloride c-Jun N-terminal kinase promotes stem

c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun

heterobifunctional protein crosslinking reagent that is commonly used to crosslink haptens to carrier proteins and enzymes to antibodies

Smiles: NC1=NC(NC2=CC=C(C=C2)S(N)(=O)=O)=NN1C(=O)C1=C(F)C=CC=C1F

2015 Jan 8

Rivaroxaban (Xarelto) yl)ethane-1 2-diamine hydrochloride c-Jun N-terminal kinase promotes stemRivaroxaban, also known as BAY 59 7939, is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. If approved by the United States FDA, it will be marketed by Ortho McNeil Pharmaceutical. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 812 hours, but